Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges.
Amongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines and other potent products.
To order this report, please visit https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html
Further, glass emerged as the most preferred fabrication material used for pre-sterilized / RTU containers. Of these, majority (83%) of the containers are made of type I borosilicate glass, followed by those fabricated using type II treated soda-lime glass (10%) and type III soda-lime glass (7%). This is followed by pre-sterilized / RTU containers fabricated using plastic (29%), primarily cyclic olefin polymer. Examples include (in alphabetical order) ClearVial (MedicoPack), Daikyo Crystal Zenith Insert Needle Syringe Systems (Daikyo Seiko), Daikyo Crystal Zenith Ready to Use Vials (Daikyo Seiko) and SCHOTT TopPac sensitive (SCHOTT).
Sterilization of primary packaging systems is considered to be an essential step in the overall healthcare manufacturing process as it deactivates various forms of contaminating agents (particularly referring to bacteria, fungi, protozoa and viruses). Majority (43%) of the pre-sterilized / RTU containers are sterilized using ethylene oxide, followed by those employing steam sterilization (34%).
Presently, close to 50 companies claim to be actively involved in the manufacturing of pre-sterilized / RTU primary packaging systems. The market landscape is highly fragmented, featuring a mix of small (less than 50 employees, 17%), mid-sized (51-500 employees, 37%), large (501-1,000 employees, 2%) and very large (more than 1,000 employees, 44%) companies. The pre-sterilized / RTU packaging manufacturers market is fragmented, featuring the presence of established players as well as new entrants, which are well distributed across different geographical regions. Examples of established players include (in decreasing order of experience) Gerresheimer (1864), Sartorius (1870), SCHOTT (1884), DWK Life Sciences (1887), SGD Pharma (1896) and Becton, Dickinson and Company (1897).
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Pharmaceutical packaging can also enhance the appearance of your pharma products.
But, it will help if you customize the packaging.
Custom pharmaceutical boxes can help you protect your products.
They can also make them stand out.
Customization allows you to tailor your packaging per your needs.https://superprintingservices.blogspot.com/2021/10/best-custom-pharmaceutical-packaging.html
UpMarketResearch offers a latest published report on “Global Vials Primary Packaging Market Industry Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report.
It presents a comparative detailed analysis of all the regional and major player segments, offering readers a better knowledge of areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the global market.
Vials Primary Packaging market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.
The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research London Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link Key Market Insights Over 170 RNAi therapeutics are currently under development Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage.
The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014Majority of these were patent applications (59%), followed by granted patents (40%).
USD 5.4+ billion invested by both private and public investors, since 2014Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019.
